SCHEMBL902002

SCHEMBL902002

c1ccc(COC2CCNCC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.66
SLC6A4 P31645 6/20 0.66
SLC6A3 Q01959 6/20 0.66
HTR2C P28335 2/20 0.66
HTR2B P41595 2/20 0.66
HTR2A P28223 1/20 0.66
HTR7 P34969 1/20 0.66
HTR3A P46098 1/20 0.66
HTR4 Q13639 1/20 0.66
HRH1 P35367 4/20 0.56
KCNH2 Q12809 2/20 0.54
GBA1 P04062 1/20 0.53
HTR1A P08908 3/20 0.53
OPRM1 P35372 2/20 0.51
OPRL1 P41146 2/20 0.51
DPP4 P27487 1/20 0.51
TMEM97 Q5BJF2 1/20 0.49
CARM1 Q86X55 1/20 0.49
PRMT6 Q96LA8 1/20 0.49
SIGMAR1 Q99720 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1532893 0.98 SLC6A2 (0.64) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
SCHEMBL21493566 0.93 SLC6A2 (0.59) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
Hydrochloric Acid SCHEMBL20268068 0.92 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
SCHEMBL27691003 0.90 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
SCHEMBL5535392 0.90 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
SCHEMBL110365 0.89 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
SCHEMBL943620 0.89 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
SCHEMBL2978516 0.89 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
Hydrochloric Acid SCHEMBL2520909 0.87 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
Hydrochloric Acid SCHEMBL2173176 0.87 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. 2023-01-12 US claimed
EP-4058145-A1 HETEROCYCLIC TRPML1 AGONISTS Libra Therapeutics, Inc. (US) 2022-09-21 EP claimed
WO-2021094974-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. (US) 2021-05-20 WO claimed
EP-3821947-A1 HETEROCYCLIC TRPML1 AGONISTS Libra Therapeutics, Inc. (US) 2021-05-19 EP claimed
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF GENOSCO INC (US) 2026-04-23 US disclosed
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FUJIFILM CORPORATION (JP) 2025-10-23 US disclosed
EP-4267574-B1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS INC (US) 2025-04-23 EP disclosed
CN-119816484-A Novel piperazine derivative or salt thereof and pharmaceutical composition 富士胶片株式会社 2025-04-11 CN disclosed
CN-119684317-A Macrocyclic compound and application thereof 郑州德迈药业有限公司 2025-03-25 CN disclosed
US-12258354-B2 AhR modulators IDEAYA BIOSCIENCES, INC. (US) 2025-03-25 US disclosed
CN-115427409-B Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists 拉夸里亚创药株式会社 2025-02-25 CN disclosed
WO-1998025901-A1 INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI (FR) 1998-06-18 WO disclosed
WO-1998008842-A1 CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-05 WO disclosed
US-5714498-A Benzimidazole derivatives MERCK, SHARP, & DOHME, LTD. (GB) 1998-02-03 US disclosed
WO-1997018201-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1997-05-22 WO disclosed
EP-0689535-A1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1996-01-03 EP disclosed
WO-1994021615-A1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-09-29 WO disclosed
CN-1090272-A Novel substituted azetidinones as anti-inflammatory and anti-allergic agents MERCK & CO INC (US) 1994-08-03 CN disclosed
EP-0015817-A1 Piperidine derivatives, process for their preparation and their use in therapeutical compositions METABIO-JOULLIE Société anonyme: (FR) 1980-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF CRBN, PSMB3, PSMB1 SLC6A2 4398/4885SLC6A4 3979/4885SLC6A3 1963/4885
US-12258354-B2 AhR modulators AHR, ARNT, RORB SLC6A2 4030/4885SLC6A4 3820/4885SLC6A3 3987/4885
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS TRPM7, TRPM2, TRPM5 SLC6A2 1153/4885SLC6A4 1066/4885SLC6A3 1191/4885
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION ABCB11, ABCC1, SLC11A2 SLC6A2 201/4885SLC6A4 440/4885SLC6A3 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.